1. Home
  2. APRE vs AIHS Comparison

APRE vs AIHS Comparison

Compare APRE & AIHS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Aprea Therapeutics Inc.

APRE

Aprea Therapeutics Inc.

HOLD

Current Price

$0.80

Market Cap

10.6M

Sector

Health Care

ML Signal

HOLD

AIHS

Senmiao Technology Limited

HOLD

Current Price

$1.26

Market Cap

5.7M

Sector

Finance

ML Signal

HOLD

Company Overview

Basic Information
Metric
APRE
AIHS
Founded
2006
2014
Country
United States
China
Employees
N/A
N/A
Industry
Biotechnology: Biological Products (No Diagnostic Substances)
Finance: Consumer Services
Sector
Health Care
Finance
Exchange
Nasdaq
Nasdaq
Market Cap
10.6M
5.7M
IPO Year
2019
2017

Fundamental Metrics

Financial Performance
Metric
APRE
AIHS
Price
$0.80
$1.26
Analyst Decision
Strong Buy
Analyst Count
2
0
Target Price
$4.10
N/A
AVG Volume (30 Days)
342.8K
26.1K
Earning Date
05-13-2026
02-13-2026
Dividend Yield
N/A
N/A
EPS Growth
21.22
14.63
EPS
N/A
N/A
Revenue
N/A
$3,389,072.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.55
$0.25
52 Week High
$2.22
$8.26

Technical Indicators

Market Signals
Indicator
APRE
AIHS
Relative Strength Index (RSI) 45.71 43.21
Support Level $0.57 $1.10
Resistance Level $0.81 $1.28
Average True Range (ATR) 0.11 0.09
MACD -0.01 -0.00
Stochastic Oscillator 14.54 13.79

Price Performance

Historical Comparison
APRE
AIHS

About APRE Aprea Therapeutics Inc.

Aprea Therapeutics Inc is a clinical-stage precision medicine oncology company focused on the discovery and development of targeted therapies for patients with biomarker-defined cancers. It develops small molecule inhibitors designed to exploit genetic mutations in cancer to widen the therapeutic window and is intended to make treatments more effective at destroying cancer cells while sparing healthy tissue. The company's pipeline of clinical and preclinical programs includes APR-1051, a WEE1 inhibitor; ATRN-119 (Mosipasertib), an oral small molecule inhibitor of ataxia telangiectasia and Rad3-related, or ATR; and an early-stage program, APR-1602. These candidates are being developed for broad applications in cancer treatment.

About AIHS Senmiao Technology Limited

Senmiao Technology Ltd is a holding company. Along with its subsidiaries, it is engaged in facilitating automobile transactions and offering related services. The group's business activities include providing car rental services to individual customers with lease term no more than twelve months; leasing and servicing of new energy vehicles; offering services to automobile purchasers throughout the purchase process; providing management and related services to Partner Platforms and other companies; automobile financing; and providing other related supporting services to customers. The majority of the group's revenue is generated from its automobile rental business.

Share on Social Networks: